Drug intelligence / Profile preview

XBH115

Development stage: Preclinical
Lead developer: GV20 Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

XBH115 is a bispecific antibody currently in the discovery phase of development by GV20 Oncotherapy. It is specifically designed to target neuro-inflammation by engaging two distinct binding sites or biological targets within neuro-inflammatory pathways. By utilizing a bispecific format, the drug aims to achieve a more precise modulation of the immune response in the central nervous system compared to monospecific therapies. As of the current pipeline disclosure, the specific molecular targets for XBH115 have not been publicly identified.

Beyond the preview

Go deeper on XBH115.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XBH115.

Explore the full profile